|
注册号: Registration number: |
ChiCTR2300075720 |
|
最近更新日期: Date of Last Refreshed on: |
2024-02-14 16:39:43 |
|
注册时间: Date of Registration: |
2023-09-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
新型冠状病毒病的发热门诊诊治流程合理化探究 |
|
Public title: |
Improvement of COVID-19 diagnostic algorithm in fever clinics |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新型冠状病毒病的发热门诊诊治流程合理化探究 |
|
Scientific title: |
Improvement of COVID-19 diagnostic algorithm in fever clinics |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
钱奕亦 |
研究负责人: |
钱奕亦 |
|
Applicant: |
Qian Yiyi |
Study leader: |
Qian Yiyi |
|
申请注册联系人电话: Applicant telephone: |
+86 139 1891 1932 |
研究负责人电话:
Study leader's |
+86 139 1891 1932 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
465749065@163.com |
研究负责人电子邮件: Study leader's E-mail: |
465749065@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区枫林路180号 |
研究负责人通讯地址: |
上海市徐汇区枫林路180号 |
|
Applicant address: |
Fenglin Road 180th, Xuhui, Shanghai |
Study leader's address: |
Fenglin Road 180th, Xuhui, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属中山医院 |
||
|
Applicant's institution: |
Zhongshan Hospital, Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属中山医院 |
||
|
Affiliation of the Leader: |
Zhongshan Hospital, Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
B2023-234 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属中山医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Zhongshan Hospital, Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-07-31 00:00:00 | ||
|
伦理委员会联系人: |
复旦大学附属中山医院伦理办公室 |
||
|
Contact Name of the ethic committee: |
Ethics Department of Zhongshan Hospital, Fudan University |
||
|
伦理委员会联系地址: |
上海市徐汇区枫林路180号 |
||
|
Contact Address of the ethic committee: |
Fenglin Road 180th, Xuhui, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 3158 7871 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属中山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongshan Hospital, Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区枫林路180号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Fenglin Road 180th, Xuhui, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self collecting |
||||||||||||||||||||||
|
研究疾病: |
新型冠状病毒病 |
||||||||||||||||||||||
|
Target disease: |
COVID-19 |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
本研究拟通过回顾性分析就诊我院发热门诊的新冠患者的临床表现及辅助检查资料,主要目的是总结其临床特点; 次要目的:探究发热门诊接诊时合理化的诊治流程,如肺部 CT 选择的时机、抗病毒药物及糖皮质激素类药物的选择等,为未来可能出现的疫情反复提供参考依据 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to retrospectively analyze the clinical manifestations and auxiliary examinations of COVID-19 patients in our hospital's fever clinic. The main purpose is to summarize their clinical characteristics. The secondary purpose is to explore the rational diagnosis and treatment process when receiving patients in the fever clinic, such as the timing of selecting lung CT, the selection of antiviral drugs and glucocorticoids, etc., in order to provide reference for possible future outbreaks. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.明确混杂其余病原体(如细菌、真菌、其余病毒等)感染或混杂其余可能发热因素的复杂患者; 2.发热病程超过2周者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with unclear mixed infections with other pathogens (such as bacteria, fungi, other viruses, etc.) or mixed with other possible fever causes; 2.Patients with a fever lasting more than 2 weeks. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-04-01 00:00:00至 To 2023-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-09-20 00:00:00 至 To 2023-10-12 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
论文发表 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Publication |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统(Electronic Data Capture, EDC) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |